Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice.

Parikh SA, Achenbach SJ, Call TG, Rabe KG, Ding W, Leis JF, Kenderian SS, Chanan-Khan AA, Koehler AB, Schwager SM, Muchtar E, Fonder AL, McCullough KB, Nedved AN, Smith MD, Slager SL, Kay NE, Finnes HD, Shanafelt TD.

Cancer Med. 2020 Mar 18. doi: 10.1002/cam4.2998. [Epub ahead of print]

2.

The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor.

Wang Y, Rabe KG, Bold MS, Shi M, Hanson CA, Schwager SM, Call TG, Kenderian SS, Muchtar E, Hayman SR, Koehler AB, Fonder AL, Chanan-Khan AA, Van Dyke DL, Slager SL, Kay NE, Ding W, Leis JF, Parikh SA.

Haematologica. 2020 Jan 23. pii: haematol.2019.240564. doi: 10.3324/haematol.2019.240564. [Epub ahead of print] No abstract available.

3.

Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare.

Hampel PJ, Call TG, Ding W, Muchtar E, Kenderian SS, Wang Y, Leis JF, Witzig TE, Koehler AB, Fonder AL, Schwager SM, Rabe KG, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA.

Am J Hematol. 2020 Mar;95(3):E57-E60. doi: 10.1002/ajh.25690. Epub 2019 Dec 13. No abstract available.

PMID:
31788844
4.

The Henna pigment Lawsone activates the Aryl Hydrocarbon Receptor and impacts skin homeostasis.

Lozza L, Moura-Alves P, Domaszewska T, Lage Crespo C, Streata I, Kreuchwig A, Puyskens A, Bechtle M, Klemm M, Zedler U, Silviu Ungureanu B, Guhlich-Bornhof U, Koehler AB, Stäber M, Mollenkopf HJ, Hurwitz R, Furkert J, Krause G, Weiner J 3rd, Jacinto A, Mihai I, Leite-de-Moraes M, Siebenhaar F, Maurer M, Kaufmann SHE.

Sci Rep. 2019 Jul 26;9(1):10878. doi: 10.1038/s41598-019-47350-x.

5.

Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center.

Wang Y, Tschautscher MA, Rabe KG, Call TG, Leis JF, Kenderian SS, Kay NE, Muchtar E, Van Dyke DL, Koehler AB, Schwager SM, Slager SL, Parikh SA, Ding W.

Haematologica. 2020 Mar;105(3):765-773. doi: 10.3324/haematol.2019.224121. Epub 2019 Jun 13.

6.

Probable Invasive Pulmonary Cryptococcosis and Possible Cryptococcal Empyema in CLL Treated With Frontline Ibrutinib.

Koehler AB, Vijayvargiya P, Ding W.

Mayo Clin Proc. 2019 May;94(5):915-917. doi: 10.1016/j.mayocp.2019.02.002. No abstract available.

PMID:
31054610
7.

Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice.

Hampel PJ, Ding W, Call TG, Rabe KG, Kenderian SS, Witzig TE, Muchtar E, Leis JF, Chanan-Khan AA, Koehler AB, Fonder AL, Schwager SM, Slager SL, Shanafelt TD, Kay NE, Parikh SA.

Leuk Lymphoma. 2019 Nov;60(11):2712-2719. doi: 10.1080/10428194.2019.1602268. Epub 2019 Apr 24.

PMID:
31014142
8.

cGAS facilitates sensing of extracellular cyclic dinucleotides to activate innate immunity.

Liu H, Moura-Alves P, Pei G, Mollenkopf HJ, Hurwitz R, Wu X, Wang F, Liu S, Ma M, Fei Y, Zhu C, Koehler AB, Oberbeck-Mueller D, Hahnke K, Klemm M, Guhlich-Bornhof U, Ge B, Tuukkanen A, Kolbe M, Dorhoi A, Kaufmann SH.

EMBO Rep. 2019 Apr;20(4). pii: e46293. doi: 10.15252/embr.201846293. Epub 2019 Mar 14.

9.

Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.

Paludo J, Abeykoon JP, Shreders A, Ansell SM, Kumar S, Ailawadhi S, King RL, Koehler AB, Reeder CB, Buadi FK, Dispenzieri A, Lacy MQ, Dingli D, Witzig TE, Go RS, Gonsalves WI, Kourelis T, Warsame R, Leung N, Habermann TM, Hayman S, Lin Y, Kyle RA, Rajkumar SV, Gertz MA, Kapoor P.

Ann Hematol. 2018 Aug;97(8):1417-1425. doi: 10.1007/s00277-018-3311-z. Epub 2018 Apr 3.

PMID:
29610969
10.

The Recombinant BCG ΔureC::hly Vaccine Targets the AIM2 Inflammasome to Induce Autophagy and Inflammation.

Saiga H, Nieuwenhuizen N, Gengenbacher M, Koehler AB, Schuerer S, Moura-Alves P, Wagner I, Mollenkopf HJ, Dorhoi A, Kaufmann SH.

J Infect Dis. 2015 Jun 1;211(11):1831-41. doi: 10.1093/infdis/jiu675. Epub 2014 Dec 11.

PMID:
25505299
11.

AhR sensing of bacterial pigments regulates antibacterial defence.

Moura-Alves P, Faé K, Houthuys E, Dorhoi A, Kreuchwig A, Furkert J, Barison N, Diehl A, Munder A, Constant P, Skrahina T, Guhlich-Bornhof U, Klemm M, Koehler AB, Bandermann S, Goosmann C, Mollenkopf HJ, Hurwitz R, Brinkmann V, Fillatreau S, Daffe M, Tümmler B, Kolbe M, Oschkinat H, Krause G, Kaufmann SH.

Nature. 2014 Aug 28;512(7515):387-92. doi: 10.1038/nature13684. Epub 2014 Aug 13.

PMID:
25119038

Supplemental Content

Loading ...
Support Center